Barclays PLC Novo Nordisk A S Put Options Transaction History

Barclays PLC

14 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 15, 2024	BUY	$119.07 - $145.42 $89.3 Million - $109 Million	750,000 New	750,000 $89.3 Million
Q3 2020 Nov 12, 2020	SELL	$63.69 - $70.22 $76,428 - $84,264	-1,200 Reduced 6.52%	17,200 $1.19 Million
Q2 2020 Aug 12, 2020	SELL	$58.54 - $67.94 $316,116 - $366,876	-5,400 Reduced 22.69%	18,400 $1.21 Million
Q1 2020 May 13, 2020	SELL	$49.46 - $64.78 $949,632 - $1.24 Million	-19,200 Reduced 44.65%	23,800 $1.43 Million
Q4 2019 Feb 10, 2020	BUY	$49.86 - $58.26 $947,340 - $1.11 Million	19,000 Added 79.17%	43,000 $2.49 Million
Q3 2019 Nov 14, 2019	BUY	$47.54 - $53.43 $941,292 - $1.06 Million	19,800 Added 471.43%	24,000 $1.24 Million
Q2 2019 Aug 14, 2019	BUY	$46.79 - $52.47 $79,543 - $89,199	1,700 Added 68.0%	4,200 $214,000
Q1 2019 May 15, 2019	SELL	$46.36 - $52.63 $120,536 - $136,838	-2,600 Reduced 50.98%	2,500 $131,000
Q4 2018 Feb 14, 2019	SELL	$41.54 - $47.25 $186,930 - $212,625	-4,500 Reduced 46.88%	5,100 $235,000
Q3 2018 Nov 14, 2018	SELL	$46.76 - $51.24 $3.39 Million - $3.71 Million	-72,500 Reduced 88.31%	9,600 $453,000
Q2 2018 Aug 14, 2018	BUY	$44.29 - $50.42 $2.92 Million - $3.33 Million	66,000 Added 409.94%	82,100 $3.79 Million
Q1 2018 May 15, 2018	SELL	$48.49 - $58.14 $2.35 Million - $2.82 Million	-48,500 Reduced 75.08%	16,100 $793,000
Q4 2017 Feb 14, 2018	BUY	$47.53 - $53.73 $2.71 Million - $3.07 Million	57,100 Added 761.33%	64,600 $3.47 Million
Q3 2017 Nov 14, 2017	BUY	$41.15 - $49.22 $308,625 - $369,150	7,500	7,500 $361,000

1,957

320M

5.49M

7.78M

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $197B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.